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a b s t r a c t
Long-lived pools of latently infected cells are a signiﬁcant barrier to the development of a cure for HIV-1
infection. A better understanding of the mechanisms of reactivation from latency is needed to facilitate
the development of novel therapies that address this problem. Here we show that chemical inhibitors of
the sulfonation pathway prevent virus reactivation, both in latently infected J-Lat and U1 cell lines and in
a primary human CD4þ T cell model of latency. In each of these models, sulfonation inhibitors decreased
transcription initiation from the HIV-1 promoter. These inhibitors block transcription initiation at a step
that lies downstream of nucleosome remodeling and affects RNA polymerase II recruitment to the viral
promoter. These results suggest that the sulfonation pathway acts by a novel mechanism to regulate
efﬁcient virus transcription initiation during reactivation from latency, and further that augmentation of
this pathway could be therapeutically useful.
& 2014 Published by Elsevier Inc.
Introduction
The development of highly active antiretroviral therapy
(HAART) has dramatically improved the prognostic outlook for
HIV-1 patients in the developed world. However, the success of
this therapy is limited by latent viral reservoirs that persist during
therapy and reseed infection if treatment is interrupted (Chun
et al., 2000; Davey et al., 1999; Imamichi et al., 2001). Early
estimates predicted that these reservoirs would eventually dimin-
ish during a prolonged treatment, but it is now clear that latent
reservoirs will persist throughout the lifetime of most patients
under the current treatment regimen (Finzi et al., 1999; Siliciano et
al., 2003). This necessitates continuous therapy and creates several
problems, including high cost, poor adherence, and drug resis-
tance. Even in adherent patients, chronic exposure to both latent
virus production and antiretrovirals appears to increase the risk of
developing non-AIDS deﬁning illnesses such as cardiovascular
disease, diabetes, liver disease, and cancer (Bedimo, 2008;
Samaras, 2009; Weber et al., 2006). For these reasons, one of the
major goals of HIV-1 antiretroviral research is to develop a therapy
that targets latently infected cells to facilitate drug-free remission
of disease (Richman et al., 2009). Achieving this goal will require a
more complete understanding of the mechanisms governing
latency and virus reactivation so that novel approaches can be
developed that speciﬁcally target viral reservoirs.
Viral reservoirs that persist in HAART-treated patients typically
consist of long-lived cells that carry integrated proviral DNA
(Pierson et al., 2000). Monocytes and macrophages have been
suggested to serve as latent reservoirs because they are resistant to
the cytopathic effects of HIV-1 infection. These cells can also
disseminate virus to immunologically privileged sites such as the
brain, where they can endure for months or even years (Cosenza
et al., 2002; Gartner et al., 1986; Lassmann et al., 1993; Williams
et al., 2001).
The best-characterized viral reservoir exists in resting CD4þ T
cells, which typically carry markers characteristic of memory
cells (Brenchley et al., 2004; Chun et al., 1997; Finzi et al., 1997;




0042-6822/& 2014 Published by Elsevier Inc.
n Corresponding author at: Nomis Center for Immunobiology and Microbial
Pathogenesis, The Salk Institute for Biological Studies, 10010 N. Torrey Pines Rd.,
La Jolla, CA 92037, USA. Tel.: þ1 858 453 4100.
E-mail address: jyoung@salk.edu (J.A.T. Young).
Virology 471-473 (2014) 1–12
Wong et al., 1997). These cells can either become infected when
they are activated and survive contraction to become infected
memory cells or they can become directly infected while in a
resting state (Cameron et al., 2010; Han et al., 2007; Jordan et al.,
2003; Spina et al., 1995). Because they are not actively producing
virus, infected memory CD4þ T cells can be extremely long-lived.
Upon activation, these cells are also capable of rapidly expanding
and reseeding infection during treatment interruption (Siliciano
et al., 2003). The combination of longevity and lack of actively
replicating virus makes them difﬁcult to eliminate with current
therapies. Recent evidence suggests that patients that can control
HIV infection in the absence of drug treatment are more likely to
have unusually low levels of latent virus in long-lived CD4þ T cell
subsets (Saez-Cirion et al., 2013).
Initially, mechanisms that govern HIV latency in CD4þ T cells
were characterized using established cell line-based models of
virus latency. Generally, these mechanisms reduce the efﬁciency of
proviral transcription. The site of integration is partly responsible
for this transcriptional suppression. In latently infected cells, the
provirus tends to reside either in compacted heterochromatic
regions or in very highly expressed genes that cause transcrip-
tional interference (Han et al., 2004; Lenasi et al., 2008; Lewinski
et al., 2005). Low transcriptional levels during latency can also
result from decreased availability or activity of transcriptional
factors that are dependent on T cell activation. Similarly, resting
T cells have increased activity of repressors that drive chromatin
condensation through recruitment of histone deacetylases (HDACs)
(Coull et al., 2000; Hsia and Shi, 2002; Imai and Okamoto, 2006; Jiang
et al., 2007; Marban et al., 2007; Tyagi and Karn, 2007; Williams and
Greene, 2007).
Activation of CD4þ T cells increases the availability of NF-κB,
NFAT, and AP-1, leading to recruitment of co-activators to the HIV-
1 LTR (Williams and Greene, 2007). The associated co-activators
have histone acetyltransferase activity that cooperates with the
ATP-dependent chromatin remodeling complex to displace nuc-1,
the nucleosome that masks the transcription start site in the HIV-1
LTR during latency (Verdin et al., 1993). Nuc-1 displacement allows
recruitment of the pre-initiation transcription complex and active
viral mRNA production. The viral regulatory Tat protein increases
the efﬁciency of this process by promoting recruitment of the
positive transcriptional elongation factor (P-TEFb) and the SWI/
SNF chromatin remodeling complex (Williams and Greene, 2007).
These results indicate that there are several obstacles to
efﬁcient LTR-based transcription in latently infected CD4þ T cells
and that the alleviation of any one of these mechanisms can
activate viral replication in at least a subset of these cells. The
development of successful strategies for eliminating viral reser-
voirs will likely require a combinatorial approach in which several
of the dominant mechanisms governing latency are targeted.
Indeed, several studies suggest that combinations of activating
stimuli are often much more effective than individual compounds
at inducing HIV reactivation in cellular models of latency
(Bartholomeeusen et al., 2012; Boehm et al., 2013; Burnett et al.,
2010; Perez et al., 2010; Reuse et al., 2009; Zhu et al., 2012).
We have previously shown that the cellular sulfonation path-
way plays an important role in regulating HIV-1 gene expression
(Bruce et al., 2008). Sulfonation is the transfer of a sulfonate
group (SO31) from the universal donor 30-phosphoadenosine
50-phosphosulfate (PAPS), generated by PAPS synthases (PAPSS1
or PAPSS2), to a hydroxyl or amino-group on an acceptor molecule.
Our forward genetic screen revealed that the PAPS synthases were
important for expression from the viral promoter of some (HIV-1
and murine leukemia virus), but not all (avian sarcoma and
leucosis virus) retroviruses (Bruce et al., 2008). These effects were
phenocopied with two chemical inhibitors of the sulfonation
pathway, chlorate and guaiacol (Bruce et al., 2008; Hortin et al.,
1988). These studies also indicated that these sulfonation inhibi-
tors speciﬁcally inﬂuence de novo virus gene expression since they
were effective at reducing provirus transcription immediately
following virus infection but had no effect when added to cells
that already contained actively expressed proviral DNA (Bruce
et al., 2008).
In the present study, we have used these well-characterized
inhibitors to study the role of sulfonation in latency models where
sulfonation was otherwise difﬁcult to disrupt. We show that these
sulfonation inhibitors block efﬁcient virus reactivation in estab-
lished cell line models and in a primary CD4þ T-cell model of
virus latency and that they can act by preventing efﬁcient recruit-
ment of RNA polymerase (pol) II to the virus promoter.
Results
Reactivation of the HIV-1 LTR is blocked by sulfonation inhibitors
To explore the role of sulfonation in reactivation from HIV-1
latency that has been established by different mechanisms, we
used three types of well characterized latently infected cell lines:
full length J-Lat clones, minigenome J-Lat clones, and promono-
cytic U1 cells.
The J-Lat 6.3 and 9.2 cells are clonal lines that contain
transcriptionally silent full length HIV-1 provirus in which the
Env gene is interrupted and nef is replaced with GFP to allow
monitoring of reactivation by a ﬂuorescence-based assay (Jordan
et al., 2003). In J-Lat 6.3 cells, NF-κB p50 homodimers promote
HDAC1 binding to the viral promoter and create a closed chroma-
tin conformation that silences LTR expression (Williams et al.,
2006). In J-Lat 9.2 cells, the latent provirus is integrated into the
highly expressed PP5 gene. PP5 transcription causes transcriptional
interference that blocks expression of the proviral genome (Lenasi
et al., 2008). In both of these cell lines, DNA methylation within
CpG islands in the viral promoter contributes to transcriptional
silencing (Blazkova et al., 2009). Treatment with chlorate during
reactivation with TNF-α alone or in combination with the HDAC
inhibitor trichostatin A (TSA) decreased the degree of reactivation
in J-Lat 6.3 cells by 2.7 and 9-fold (Fig. 1A and B). Similarly, in J-Lat
9.2 cells, treatment with chlorate decreased TNF-α-mediated
reactivation by 2-fold and TNF-α plus TSA-mediated reactivation
by 6-fold (Fig. 1A and B). Under these conditions, chlorate treat-
ment inhibited sulfonation as expected (judged by reduced cell
surface sulfotyrosine levels in J-Lat 6.3 cells) (Fig. 1D) and it did not
cause any signiﬁcant changes in cell viability (Fig. 1C). These data
suggest that the sulfonation pathway can regulate reactivation
from latency in cells where that latent state was originally
maintained by NF-κB p50 homodimers or transcriptional
interference.
To determine both the contribution of integration sites as well
as viral proteins to the effect of sulfonation on reactivation, we
next analyzed the minigenome J-Lat model cell lines. These cells
contain a minimal HIV construct in which the HIV-1 LTR drives
expression of GFP and Tat in the absence of additional viral
proteins (Jordan et al., 2003). In J-Lat A1 cells, this construct is
integrated into an intergenic region at position ChXp21.1 (Jordan
et al., 2003). In J-Lat A2 cells, transcriptional interference drives
latency due to integration into the highly expressed UTX gene
(Gallastegui et al., 2011). In these cells, chromatin reassembly
factors such as Spt6 can reestablish a repressive chromatin
environment in the wake of RNA pol II, likely through coordination
with histone deacetylases (Gallastegui et al., 2011). In J-Lat A7
cells, the construct is integrated into alphoid repetitive DNA,
a component of the centromeric heterochromatin. In each of these
models, sulfonation inhibition decreased reactivation triggered
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with TNF-α and TSA (Fig. 2A and B). While the overall degree of
inhibition varied in different clonal cell lines, the inhibition of
reactivation by chlorate was consistent for all the J-Lat models
tested. Taken together, these results indicate that sulfonation
inhibitors block reactivation in the context of multiple different
mechanisms that drive viral latency in the J-Lat model system and
that this effect is independent of viral proteins with the possible
exception of Tat.
Several lines of evidence indicate that restricted levels of Tat
lead to blocks in transcription elongation that can drive HIV-1
latency (Lassen et al., 2004; Taube and Peterlin, 2013). We used the
promonocytic U1 cell line to assess the role of sulfonation in the
context of latency that is induced by elongation defects. U1 cells
contain two proviral HIV-1 genomes, one with a mutation that
prevents Tat production and the other with a mutation that
decreases Tat activity (Emiliani et al., 1998). U1 cells were activated
overnight and simultaneously treated with sulfonation inhibitors.
The production of intracellular p24 was used to monitor virus
reactivation (Fig. 3). Either chlorate or the combination of chlorate
and guaiacol inhibited reactivation with the protein kinase C
Fig. 1. Sulfonation inhibitors block HIV-1 reactivation from latency in J-Lat cells. (A) Flow cytometric analysis of latent HIV-1 reactivation in the indicated J-Lat cells lines that
were unactivated or activated for 16 h with 20 ng/ml TNF-α7200 nM TSA in the presence (shaded curve) or absence of 90 mM chlorate (open solid curve). Histograms
indicate GFP ﬂuorescence. Gates indicate GFP-positive cells. (B, C) Bar graph representation shows the mean average values for at least three independent experiments,
conducted as described in (A). The cells were assayed for GFP ﬂuorescence using ﬂow cytometry (B) or for viable cell number using a chemiluminescent assay (C). Error bars
indicate standard deviation and statistical signiﬁcance was determined by paired Student's t-test, npo0.05, and nnpo0.01. (D) J-Lat 6.3 cells were treated for 16 h with the
indicated concentration of chlorate, then stained with anti-sulfotyrosine antibody or isotype-matched control antibody and propidium iodide. Flow cytometry was used to
quantify sulfotyrosine levels on live cells, shown as mean ﬂuorescence intensity (MFI). Mean and SEM are shown from three replicate experiments. Results are normalized to
control cells in which chlorate was absent. Statistical signiﬁcance was determined by one sample t-test, nnpo0.01.
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activator prostratin (Pro) (10-fold and 26-fold, respectively), TNF-α
(3-fold and 11-fold, respectively), prostratin with TSA (4-fold and
6-fold, respectively), or TNF-α with TSA (9-fold and 10-fold, respec-
tively) (Fig. 3A). In each of these cases, neither chlorate nor the
combination of chlorate and guaiacol signiﬁcantly decreased cell
viability (Fig. 3B). These data indicate that the sulfonation pathway
is important for reactivation in the context of latency that is
maintained by defects in elongation. Thus, in several established
models for HIV latency in which different mechanisms have been
shown to maintain the latent state, sulfonation pathway inhibitors
consistently block reactivation with multiple stimuli.
Sulfonation pathway inhibitors reduce the level of initiated HIV-1
transcripts following reactivation
To determine if the sulfonation pathway inhibitors impact HIV-
1 transcription initiation or elongation, we performed a quantita-
tive RT-PCR analysis of viral RNA with 2 different oligonucleotide
primer sets (Fig. 4A). The ﬁrst, designated as the “initiated” set
ampliﬁes the 50-end of the viral transcript (residues þ1 to þ59), a
region that contains the viral TAR element, which is under
Tat-dependent transcriptional elongation control (Adams et al.,
1999; Lassen et al., 2004). These “initiated” primers will amplify all
transcripts that are successfully initiated, both abortive transcripts
and those for which elongation is successfully completed. The
second pair of oligonucleotide primers, designated as the “elon-
gated” set, was used to amplify a downstream region (residues
þ107 to þ189), which is beyond the two major pause sites within
the HIV LTR at þ50 and þ119 (Jadlowsky et al., 2014). As a result,
this primer set only ampliﬁes transcripts in which HIV-1 Tat has
facilitated transcriptional elongation (Ott et al., 2011). In J-Lat
6.3 cells, chlorate treatment signiﬁcantly reduced the levels of
both types of transcript at early times post-activation (Fig. 4B and
C). Within 4 h of activation, there was a 2-fold reduction in
initiated transcripts and a 9-fold reduction in elongated tran-
scripts. The greater effect on elongated transcripts in these
cell lines might result from the low level of transcription initiation
that takes place during latency in the absence of sufﬁcient Tat
production. Within 6 h of activation, initiated and elongated
transcripts were reduced 12-fold and 20-fold, respectively. Primers
that ampliﬁed a transcript in the vpr gene showed sulfonation-
dependent decreases in HIV transcription that mirrored those seen
with the initiated and elongated primer sets (data not shown).
Treatment of U1 cells with chlorate, guaiacol, or the combination
of both inhibitors led to a similar decrease in both initiated
and elongated HIV-1 transcripts (Fig. 4D and E). These data are
consistent with a model in which sulfonation pathway inhibitors
act at the level of transcription initiation.
Sulfonation does not broadly alter the expression of TNF-α and
TSA-responsive genes in Jurkat cells
The HIV-1 LTR promoter is strongly affected by transcription
factors that are upregulated during T cell activation (Williams and
Greene, 2007). Thus, it is possible that sulfonation blocks TNF-
mediated reactivation from latency by broadly disrupting TNF-α
and TSA-mediated signaling pathways. To address this question,
J-Lat 6.3 cells were treated with TNF-α and TSA in the presence or
absence of 90 mM chlorate for 6 h, then cellular RNAwas extracted
and subjected to microarray analysis. Under these conditions,
treatment with TNF-α and TSA signiﬁcantly changed the signal
of 462 probe sets, speciﬁc for 392 genes (Table S1). These genes
were most strongly enriched for a cluster of functional categories
associated with immune system development, lymphocyte activa-
tion, and apoptosis (Table S2). However, only 22 of these genes
(25 probe sets) were affected by the treatment with the sulfonation
inhibitor (Table S3) and just 2 of the genes affected by sulfonation
(CD24, DHRS2), were annotated in the lymphocyte activation cluster.
These results indicate that the sulfonation pathway selectively reg-
ulates TNF-α and TSA-induced HIV-1 gene expression.
LTR regulation by sulfonation is independent of NF-κB
Several transcription factors are known to bind to deﬁned sites
within the HIV-1 LTR. To determine if these binding sites were
required for regulation by sulfonation, we used a panel of DHIV
Fig. 2. Sulfonation inhibitors block reactivation from latency in J-Lat cells containing HIV minigenomes. (A) Flow cytometric analysis of latent HIV-1 reactivation in the
indicated J-Lat cell lines that were activated for 16 h with 20 ng/ml TNF-αþ200 nM TSA and treated without chlorate (open, thick curve), with 60 mM chlorate (open, thin
curve) or with 90 mM chlorate (shaded curve). Histograms indicate GFP ﬂuorescence. Gates indicate GFP-positive cells. (B) Bar graph representation shows the mean average
values for at least three independent experiments, conducted as described in (A). Error bars indicate standard deviation and statistical signiﬁcance was determined by paired
Student's t-test, npo0.05, nnpo0.01.
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viruses containing deﬁned LTR mutations that disrupt the binding
sites for NF-kB, NFAT, NF-IL6, and USF (Bosque and Planelles,
2009). These viruses were used to infect HOS-CD4 cells in the
presence or absence of sulfonation inhibitors, then virus infection
was quantiﬁed using qRT-PCR to measure HIV mRNA transcription.
Sulfonation inhibitors decreased transcription from each mutant
virus to the same degree as that seen with the wild type virus
(Fig. 5). This shows that these transcription factors are not
required for sulfonation-mediated regulation of LTR transcription
and suggests that sulfonation regulates a step in transcription that
occurs after these transcription factors bind the HIV-1 LTR.
Sulfonation inhibitors do not inﬂuence chromatin remodeling at
the viral promoter
Transcription initiation of the latent provirus is regulated by
nucleosome positioning. In the latent state, the HIV-1 LTR exists in
a closed conformation in which the transcription start site is
masked by the nuc-1 nucleosome (Verdin et al., 1993). During
reactivation from latency this nucleosome is remodeled, making
the start site more accessible to the core RNA pol II transcription
machinery. This alteration can be monitored by AﬂII restriction
enzyme site accessibility (Fig. 6A) (Verdin et al., 1993).
To determine if sulfonation inhibitors inﬂuence nuc-1 remodel-
ing, nuclei were extracted from cells mock-treated or treated with
several different activators. The nuclei were digested with AﬂII
before DNA was puriﬁed and digested to completion with PstI,
which cuts upstream and downstream of the viral LTR (Fig. 6A).
The digested samples were then analyzed by Southern blotting
using a viral probe corresponding to a region downstream of the
LTR U5 region (Fig. 6A). As expected, AﬂII cleaved the provirus
promoter region in activated cells (Fragment a, Fig. 6B, lanes 3, 5, 7,
and 9) but not in unactivated U1 cells (Fig. 6B, lane 1). Individual
chlorate and guaiacol treatment or treatment with both inhibitors
did not abolish nuc-1 remodeling during reactivation from latency
with different stimuli (Fig. 6B lanes 4, 6, 8, and 10 and Fig. 6C lanes
6–8). Instead, these treatments appear to promote this rearrange-
ment, even in the absence of an activating stimulus (Fig. 6B lane
2 and Fig. 6C lanes 2–4). The combination of chlorate and guaiacol
treatments gave rise to stronger nuc-1 remodeling than either
inhibitor alone (Fig. 6C, compare lanes 2–4). This suggests that
inhibition of reactivation could result from erroneous nucleosome
remodeling or that the effect of the sulfonation inhibitors on
transcription initiation takes place at a step downstream of nuc-1
remodeling.
Sulfonation inhibitors reduce RNA pol II recruitment to the HIV LTR
Chromatin immunoprecipitation (ChIP) studies were employed
to test the effect of sulfonation inhibitors on RNA pol II recruit-
ment to the HIV-1 LTR. J-Lat 6.3 cells were activated with TNF-α
and TSA, protein-DNA complexes were crosslinked and the sam-
ples subjected to immunopuriﬁcation using an antibody speciﬁc
for RNA pol II. The level of RNA pol II associated with the viral
promoter was then determined by qPCR analysis of proviral DNA.
We found that the overall levels of RNA pol II associated with
the viral promoter increased by 5.5-fold during activation with
TNF-α and TSA (p¼0.020) (Fig. 7A). By contrast, chlorate reduced
the level of RNA pol II associated with the promoter 1.9-fold
(p¼0.0040) (Fig. 7A). Even with chlorate present, there was still a
2.8-fold increase in RNA pol II levels relative to the untreated
controls, though this was not signiﬁcant (p¼0.13). This residual
recruitment could be due to the incomplete inhibition of tran-
scription by chlorate or it could indicate that chlorate affects
promoter-proximal pausing and clearance as well as RNA pol II
recruitment. The chlorate treatment did not signiﬁcantly alter the
levels of RNA pol II at the cellular GAPDH promoter used for
control purposes, indicating that the effect of the inhibitor was
speciﬁc for the viral promoter (Fig. 7B). Also, the viral promoter
was not enriched in parallel ChIP experiments performed with a
control IgG (Fig. 7A) and a non-transcribed DNA fragment was not
co-puriﬁed with the pol II antibody (Fig. 7C). We conclude that
sulfonation inhibitors block HIV-1 gene expression in these cells at
least in part by decreasing RNA pol II recruitment to the HIV-1 LTR
promoter.
Sulfonation inhibitors block transcription initiation during
reactivation in a primary CD4 T-cell model of virus latency
To assess the effects of sulfonation inhibition in a more
physiologically relevant cell system, we used an in vitro primary
CD4þ T-cell model of HIV latency. In this model, non-productive
viral infection is established in a non-dividing subpopulation of
CD4þ T cells isolated after co-culture with activated autologous
infected cells. Importantly, latent virus can be reactivated in this
model system by several physiologically relevant inducers, includ-
ing HDAC inhibitors, PKC agonists, TNF-α, and TCR engagement
(Spina et al., 2013).
Fig. 3. Sulfonation inhibitors block reactivation from latency in U1 cells. (A) U1
cells were treated for 16 h with 400 nM TSA, 5 mM Prostratin, 10 ng/ml TNF-α,
200 nM TSA and 5 mM prostratin, or 200 nM TSA and 10 ng/ml TNF-α. At the time of
activation, cells were treated with 60 mM chlorate or 60 mM chlorate and 2 mM
guaiacol. After activation for 16 h, cellular lysates were assayed by ELISA for p24
levels (A) and the viable cell number was assessed using a chemiluminescent assay
(B). The mean values from three independent experiments performed in triplicate
are shown. Error bars indicate standard error. Statistical signiﬁcance was deter-
mined by paired Student's t-test, npo0.05, nnpo0.01.
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Provirus reactivation in the latently infected resting CD4þ T
cell population was stimulated by T cell receptor activation with
immobilized α-CD3/α-CD28 antibodies for 48 h and was mon-
itored by measurement of cell-associated HIV-1 Tat mRNA expres-
sion normalized to 18S rRNA levels. Guaiacol and/or chlorate
treatment reduced the levels of induced HIV-1 Tat mRNA between
2 and 7-fold (Fig. 8A), without affecting the percentage of viable
cells (Fig. 8E). These effects were also clearly seen when the values
obtained from each experiment were normalized to the untreated
activated cell control, accounting for variation between donors in
the overall level of induced activation (Fig. 8B). To determine if the
block to virus reactivation in this primary T cell system also maps
to transcription initiation, we employed the same qRT-PCR based
approach used in Fig. 4. Indeed, treatment with chlorate and
guaiacol reduced the abundance of both RNA species greater than
10-fold (Fig. 8C and D), indicating that these inhibitors also block
transcription initiation in this primary cell model system.
Discussion
We have shown that two independent inhibitors of the
sulfonation pathway, chlorate and guaiacol, can block efﬁcient
HIV-1 reactivation in established cell lines and in a primary CD4þ
T-cell model system of virus latency. This effect is likely to be
broad-acting since previous studies in the established cell line
models showed that proviruses in these cells are maintained in the
latent state by a variety of different mechanisms including tran-
scriptional interference, inefﬁcient Tat activity, repressive DNA
methylation, transcription factor binding, or chromatin context.
Fig. 4. Sulfonation inhibitors reduce the level of initiated HIV-1 transcripts during reactivation. (A) Diagram of the HIV-1 LTR showing the location of the “initiated” and
“elongated” primer sets. (B, C) Quantitative RT-PCR measurements of initiated (B) and elongated (C) HIV-1 transcripts, normalized to a cellular GAPDH control, at different
time points post-activation following treatment of J-Lat 6.3 cells with 20 ng/ml TNF-α and 200 nM TSA790 mM chlorate. (D, E) U1 cells were mock treated or treated for 6 h
with 20 ng/ml TNF-α and 200 nM TSA75 mM guaiacol, 60 mM chlorate, or 60 mM chlorate and 2 mM guaiacol. The viral RNA species were then monitored as in panels B
and C. For panels B–E, statistically signiﬁcant differences from the mock treated controls were determined using the paired Student's t-test, *po0.05. Bars indicate the mean
and error bars indicate standard error of at least 4 independent experiments, each performed in triplicate.
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Sulfonation inhibition decreases both initiated and elongated HIV
transcripts, indicating that sulfonation decreases transcription
initiation. We also provided evidence that these inhibitors can
act downstream of nucleosome remodeling and decrease RNA
pol II recruitment to the viral promoter in the J-Lat model. By
extending the regulation of the sulfonation pathway to reactiva-
tion of virus gene expression, these results support our earlier
conclusion, based on genetic and pharmacological evidence, that
sulfonation can regulate de novo HIV-1 gene expression (Bruce
et al., 2008). Thus, these data combined with our earlier ﬁndings
(Bruce et al., 2008), provide two independent lines of evidence
that the sulfonation pathway can play a role in regulating de novo
virus gene expression, either immediately following virus infec-
tion or during reactivation from latency.
The experiments described here used chlorate and guaiacol as
tools to explore the role of the sulfonation pathway in the regula-
tion of HIV-1 latency. As described above, these compounds have
been shown to inhibit expression of newly integrated retroviral
DNA in a manner that phenocopies PAPS synthase deﬁciency (Bruce
et al., 2008). We did attempt to phenocopy the effects of the
chemical inhibitors on HIV-1 reactivation by expressing inducible
shRNAs targeting PAPSS1 and PAPSS2 in J-Lat cells. However, we
found that expression of any shRNA (including control shRNAs) in
these cells led to a modest increase in viral mRNA even in the
absence of any other added stimulus. This effect was more pro-
nounced when multiple shRNA constructs were introduced into the
same cell line. While the underlying mechanism behind these
results is unknown, this effect prevented us from using genetic
means to validate results obtained with pharmacological inhibitors.
Our ﬁnding that sulfonation inhibitors block RNA pol II recruit-
ment without decreasing chromatin remodeling is surprising, as
these two processes are generally closely linked. Indeed, we found
that sulfonation inhibitors actually increase nuc-1 remodeling.
This could be directly linked to the decrease in transcription, as in
the case of the yeast protein Fun30, which represses transcription
by altering nucleosome positioning (Byeon et al., 2013). Alterna-
tively, transcriptional repression could be independent of nucleo-
some remodeling if sulfonation inhibitors block a step that occurs
downstream of this process.
Typically, during HIV-1 reactivation from latency, nucleosomal
remodeling is associated with increased histone acetylation and
recruitment of RNA pol II (Van Lint et al., 1996; Williams et al.,
2006). However there are examples in which histone acetylation
takes place without chromatin remodeling (Kiefer et al., 2004) and
in which chromatin remodeling takes place in the absence of
histone acetylation (Klichko et al., 2006). Our studies have pin-
pointed a novel regulatory step in HIV-1 gene expression, one that
maps after chromatin remodeling and prior to RNA pol II recruit-
ment. This distinguishes the HIV-1 LTR from promoters such as the
α1-antitrypsin promoter, which is stimulated by chromatin remo-
deling that occurs after the RNA pol II preinitiation complex is fully
assembled (Soutoglou and Talianidis, 2002).
Fig. 5. NF-kB, NFAT, NF-IL6, and USF binding sites are not required for regulation by
sulfonation. HOS-CD4 cells were infected with wt DHIV or with different LTR
mutants (Bosque and Planelles, 2009) in the presence of 40 mM chlorate and 5 mM
guaiacol (light gray bars), 20 mM chlorate and 3 mM guaiacol (dark gray bars), or
no drug (normalized to 100% infection). 30 h after infection, RNA was extracted and
viral mRNA was quantiﬁed relative to cellular actin mRNA. Bars indicate the mean
of at least 3 independent experiments, each performed in triplicate.
Fig. 6. Sulfonation inhibitors do not block nuc-1 remodeling. (A) Diagram shows
the positions of nucleosomes bound to the HIV-1 LTR and the location of the AﬂII
and PstI restriction enzyme sites (Verdin et al., 1993). PstI cleaves the HIV-1
genome at the indicated site and at a site within the host genomic DNA located
upstream of the integrated provirus. The size of the fragments generated by partial
digestion with AﬂII, followed by complete digestion with PstI, is shown. (B) Nuclei
were prepared from U1 cells mock treated or treated with 400 nM TSA, 5 mM
prostratin, 10 ng/ml TNF-α, or 200 nM TSA and 5 mM prostratin in the presence or
absence of 60 mM chlorate and 2 mM guaiacol for 60 min and partially digested
with AﬂII. (C) Nuclei were prepared from U1 cells mock treated or treated with
400 nM TSA in the presence or absence of 5 mM guaiacol, 60 mM chlorate or
60 mM chlorate and 2 mM guaiacol for 60 min and partially digested with AﬂII.
After partial digestion, DNA was puriﬁed, digested to completion with PstI, and
then analyzed by Southern blot analysis using a probe corresponding to a region
located downstream of the LTR U5 region (A). The fragment that results from
cleavage with AﬂII is indicated (a). Bands located between 2000 and 3000 bp result
from cleavage of genomic DNA upstream of the proviruses. Nucleic acid molecular
size markers are indicated.
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Studies on transcription regulation in several different systems
have led to a model in which activators such as NF-κB or NFAT
recruit chromatin modiﬁers and remodelers, which allow the
subsequent formation of the RNA pol II preinitiation complex
(Malik and Roeder, 2010; Siliciano and Greene, 2011). Preinitiation
complex formation is regulated by several factors, including the
mediator complex and general transcription factors (Sikorski and
Buratowski, 2009). For example, the mediator complex can bind
the histone acetyltransferase p300, causing p300 dissociation from
the promoter and facilitating the binding of TFIID and other
components of the preinitiation complex (Black et al., 2006). Our
data support a model in which sulfonation inhibitors block the
function of one of the factors mediating preinitiation complex
assembly. Further experiments are needed to determine the effects
of the sulfonation pathway on preinitiation complex assembly at
the HIV-1 LTR.
The primary T cell model of HIV-1 latency we employed used
direct infection of resting CD4þ T cells, which represent bystan-
ders in an ongoing productive infection of proliferating T cells. This
is a relevant model system for studying HIV-1 reactivation, one
that recapitulates a number of features seen with clinical samples
(Spina et al., 2013). However, each primary cell model system has
its own merits and the clinical features of HIV-1 reactivation are
not recapitulated exactly by any single model system. Indeed,
simply removing latently infected cells from ART-treated patients
and culturing them ex vivo likely alters their responsiveness to
certain stimuli (Spina et al., 2013). The differences between model
systems is demonstrated in that sulfonation inhibitors did not
block HIV-1 reactivation in a non-polarized central memory CD4þ
T cell model (Bosque and Planelles, 2009) (data not shown).
Similarly, HDAC inhibitors were inactive in this non-polarized
central memory model, but active in the model based on bystan-
der spread (Spina et al., 2013). Further studies will be needed to
determine if the sulfonation pathway controls HIV-1 reactivation
in other latency models.
In addition, it will be important to determine whether one or
more cytosolic or golgi cellular sulfotransferases—enzymes that
use PAPS to transfer sulfonate to a target molecule (Strott, 2002)—
control HIV-1 gene expression. Once the speciﬁc sulfotransferase
(s) involved has been identiﬁed, it should become possible to
screen for compounds that augment their activity which, in turn,
would be predicted to promote more efﬁcient reactivation from
latency. In this way, the sulfonation pathway may provide a novel
target that could be used, in combination with other treatments, to
facilitate the development of a therapeutic strategy designed to
cure HIV-1 infection during a suppressive antiretroviral treatment.
Materials and methods
Cell culture and reagents
The promonocytic U1 cell line (Folks et al., 1987) and the J-Lat
6.3, 9.2, A1, A2, and A7 lines (Jordan et al., 2003) were obtained
from the AIDS Research and Reference Reagent Program (NIAID,
NIH, Bethesda, MD). Cells were grown in RPMI 1640 medium
(Gibco-BRL) supplemented with 10% fetal bovine serum, 50 U/ml
of penicillin, 50 mg/ml streptomycin at 37 1C in a humidiﬁed 95%
air/5% CO2 atmosphere.
Cells were stimulated with 200 nM trichostatin A (TSA, Sigma-
Aldrich), 5 mM prostratin (12-deoxyphorbol-13-acetate, Sigma-
Aldrich), or 20 ng/ml TNF-α (Gibco-BRL) unless otherwise indicated.
Sodium chlorate and guaiacol were obtained from Sigma-Aldrich.
All compounds were resuspended and stored as recommended by
the manufacturer, then diluted in cell culture medium immediately
before use. Viable cell number was assayed using CellTiter-Glo
reagent (Promega) following the manufacturer's instructions.
p24 ELISA
Production of HIV-1 p24 in U1 cells after reactivation for 16 h
was measured by p24 antigen capture ELISA according to manu-
facturer's instructions (Zeptometrix).
Transcriptional microarray proﬁling
J-Lat 6.3 cells were stimulated for 6 h with 20 ng/ml TNF-α and
200 nM TSA (790 mM sodium chlorate). Total RNA was isolated
using Qiagen RNeasy kits and hybridized to human U133A
2.0 microarrays using standard protocols (Affymetrix). Data were
generated from 3 independent samples per condition. Statistical
analyses were conducted using an unpaired-test version of the
VAMPIRE algorithm for microarray data (Hsiao et al., 2005).
Statistically signiﬁcant expression changes were identiﬁed using
a Bonferroni error threshold of αBonf¼0.05, which accounts for
multiple-testing errors. DAVID analysis (Huang da et al., 2009a, b),
using standard parameters and high stringency was conducted to
identify clusters of GO categories.
Real-time quantitative PCR
For J-Lat cells, lysates from 50,000 cells were used for cDNA
synthesis reactions using random oligomers according to manu-
facturer's instructions using the Cells-to-Ct kit (Life Technologies).
Fig. 7. Sulfonation inhibitors block RNA pol II recruitment to the HIV-1 LTR. Chromatin immunoprecipitation analysis of the HIV-1 proviral LTR in J-Lat 6.3 cells in the
absence of treatment, in the presence of 20 ng/ml TNF-α and 200 nM TSA, or in the presence of 20 ng/ml TNF-α, 200 nM TSA, and 90 mM chlorate. After 6 h, cells were lysed
and sonicated. Samples were immunoprecipitated with an antibody against RNA pol II or with non-speciﬁc IgG, then probed by qPCR using primers speciﬁc for the HIV-1 LTR
(A), the GAPDH promoter (B), or a region of chromosome 12 that contains no active genes (C). All graphs represent mean and standard error of at least 4 independent
experiments performed in triplicate. Where indicated, statistical signiﬁcance was determined using the paired Student's t-test, ***po0.005.
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The Cells-to-Ct kit yielded inconsistent results with U1 cells, so an
alternative method was used to purify RNA and synthesize cDNA
from these cells. Total RNA samples were isolated using the miR-
Neasy kit (Qiagen) and used to synthesize cDNA using the Quantitect
reverse transcription kit (Qiagen). Real-time PCR for detection of total
and elongated HIV-1 transcripts was performed using previously
described primers: for initiated HIV transcripts (Adams et al., 1999;
Lassen et al., 2004), HIV-START, 50-GGGTCTCTCTGGTTAGA-30 and
HIV-SHORT, 50-GGGTTCCCTAGTTAGCC-30; for Elongated HIV tran-
scripts (Konig et al., 2008), ERT2F, 50-GTGCCCGTCTGTTGTGTGAC-30
and ERT2R, 50-GGCGCCACTGCTAGAGATTT-30; for Vpr HIV transcripts,
VPR1F, 50-TGGAACAAGCCCCAGAAGACC-30 and VPR1R, 50-TGCCCAAG-
TATCCCCATAAGTTTC-30. As an input control, a primer set that detects
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA was
used: GAPDH-F, 50-CATGAGAAGTATGACAACAGCCT-30 and GAPDH-R,
50-AGTCCTTCCACGATACCAAAGT-30. PCR was performed by heating
the reaction mixture to 95 1C for 20 s and 40 cycles of 95 1C for 1 s,
60 1C for 20 s. Ampliﬁcation and detection were performed using an
ABI Prism 7900HT Fast Real-Time PCR System and Fast SYBR Green
PCR Master Mix (Life Technologies) in 384-well optical reaction
Fig. 8. Sulfonation inhibitors block transcription initiation in a primary CD4þ T-cell model of virus reactivation. Latently infected, resting CD4þ T cells were recovered from
in vitro culture (as described in the Materials and Methods section) and activated for 48 h with α-CD3/α-CD28 antibodies. Chlorate or guaiacol were added at the indicated
concentrations 2 h prior to initiation of cell activation and then maintained during the 48 h reactivation period. (A) Viral mRNA levels were measured by qRT-PCR, using
primers speciﬁc for multiply spliced HIV Tat mRNA and normalized to a cellular 18S rRNA control. The mean average values from three experiments using different donor
cells are shown. (B) Results obtained shown in (A) are shown normalized to the activated control values. (C, D) Initiated and elongated viral mRNA species were quantiﬁed
using the primers shown in Fig. 4A and normalized to a cellular 18S rRNA control. The data shown represent the mean values obtained with cells from two different
experiments using different donor cells. Error bars indicate standard deviation. (E) CD4þ T cells were activated in the presence of chlorate and/or guaiacol for 48 h with
α-CD3/α-CD28 antibodies, stained with ﬁxable violet dead cell stain, and ﬁxed with paraformaldehyde. The percent of violet-negative cells was determined by ﬂow cytometry and
normalized to a control without chlorate or guaiacol. The data shown represent the mean values of three experiments and error bars indicate standard deviation.
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plates. Duplicate 10 ml reaction mixtures contained 200 nM of the
Elongated or GAPDH PCR primer pairs or a 1 mM concentration of the
initiated primer pair. Transcript levels were determined using
standard curves prepared from plasmids containing HIV proviral
DNA or GAPDH cDNA.
For infected primary CD4þ T cells, HIV tat transcripts were
quantiﬁed using a modiﬁcation of a published method (Fischer
et al., 2002). Total cellular RNA was extracted (Qiagen RNeasy kit)
from sample aliquots of 5105 cells and qRT-PCR was performed
with the samples, uninfected T cell RNA, and the tat RNA standard
control (normalized to 25 ng input RNA). The isolated RNA was
reverse transcribed by random hexamer priming. The cDNA
products were analyzed by qPCR with primers (400 nM) directed
to cellular 18S and HIV tat: TAT-F, 50-GGCGACTGAATTGGGTGTC-30
and TAT-R, 50-TCTACTGGCTCCATTTCTTGCT-30. Probes (250 nM)
were 50-FAM, 30-Black Hole Quencher labeled (Integrated DNA
Technologies), TAT-P, TCCTCTGTCGAGTAACGCCTATTC. The stan-
dard curve for tat transcript was generated by serially diluting
the reverse transcribed, cloned RNA into uninfected cellular cDNA.
Flow cytometry analysis
J-Lat cells were mock-treated or treated for 16 h with 20 ng/ml
TNF-α or 20 ng/ml TNF-α and 200 nM TSA in the presence or
absence of the indicated concentrations of chlorate for 16 h. Cells
were ﬁxed using 1.5% formaldehyde, the percentage of live GFP-
positive cells was measured on a FACScan cytometer (Becton
Dickinson) and data were analyzed using FlowJo software (TreeStar).
Analysis was restricted to the single cell population, as deﬁned by
forward versus side scatter proﬁle.
To assay viability of primary CD4þ T cells, 106 cells were
activated with α-CD3 and α-CD28 antibodies on Dynabeads to
induce cell proliferation according to manufacturer's instructions
(Life Sciences). Cells were treated with chlorate and/or guaiacol at
the indicated concentrations for 48 h. Cells were stained according
to manufacturer's instructions in Dulbecco's phosphate buffered
saline, calcium- and magnesium-free (PBS, Life Technologies)
with the viability dye Live/Dead violet (Life Technologies) and
ﬁxed in 1% paraformaldehyde in DPBS. The number of viable,
violet-negative cells was determined on a LSRII cytometer (Becton
Dickinson).
To assess sulfotyrosine levels, 106 J-Lat 6.3 cells were treated
with the indicated levels of sodium chlorate for 16 h. Cells were
washed in staining buffer (PBS with 2% FBS), resuspended in
100 μl staining buffer with 2 μl mouse anti-human sulfotyrosine
antibody (Millipore, Cat. no. 05-1100) or 4 μl IgG2aκ mouse
isotype control (BD Biosciences, Cat. no. 553454) and incubated
at room temperature for 1.5 h in the dark. The cells were then
washed and resuspended in 200 μl staining buffer with 1 μl goat
anti-mouse AlexaFlour680-conjugated IgG (HþL) secondary anti-
body (Life Technologies) and incubated in the dark at room
temperature for 30 min. Control experiments using mouse
embryonic ﬁbroblasts lacking TPST1 and TPST2 (Westmuckett
et al., 2008) showed that this anti-human sulfotyrosine antibody
is speciﬁc for sulfotyrosine residues under these conditions. The
cells were washed, resuspended in 500 μl staining buffer with
2.5 μl 1 mg/ml propidium iodide (Life Technologies), incubated for
10 min at room temperature, washed and resuspended in staining
buffer. Sulfotyrosine levels were quantiﬁed on live (propidium
iodide negative) cells by ﬂow cytometry using a BD Accuri Flow
Cytometer.
Virus generation and viral infection
Plasmids containing defective HIV (DHIV) were mutagenized as
described (Bosque and Planelles, 2009). Single-cycle VSV-G
pseudotyped lentiviruses were generated by transient transfection
of HEK293T cells (Konig et al., 2007). To normalize infections, p24
levels were determined for viral stocks using p24 ELISA. Viruses
normalized by p24 were used to infect HOS-CD4 cells for 4 days,
then DNA was extracted using the DNeasy Blood and Tissue Kit
(Qiagen). Real time PCR was used to quantify proviral copies,
determined using the ERT2F and ERT2R primers, relative to
copies of genomic DNA, determined using primers ZASC1_51F,
50-TTGGTGACTGTCATCCTGTTTC-30 and ZASC1_51R, 50-CTAGCACC-
CATGGTTAAGGAAG-30. 104 HOS-CD4 cells were infected at a MOI
of 0.5 in the presence or absence of the indicated concentrations
of chlorate and guaiacol. After 30 h, cells were lysed, cDNA was
synthesized, and viral mRNA was quantiﬁed using the ERT2F and
ERT2R primers. Virus expression was normalized to actin mRNA,
using the actinF, 50-CCTGGCACCCAGCACAAT-30, and actinR,
50-GCCGATCCACACGGAGTACT-30 primers. QRT-PCR was used to
determine mRNA copy number as described above.
Analysis of HIV LTR nucleosome 1 (nuc-1) chromatin structure
Puriﬁed nuclei were digested with AﬂII or HinfI as described
elsewhere (Verdin et al., 1993). Puriﬁed DNA (30 mg) was digested
to completion with PstI. The fragments were separated by electro-
phoresis using 1.5% agarose gels and analyzed by Southern blot.
The virus promoter-speciﬁc probe was synthesized using PCR
products generated using the primer set EV1 and EV2 as described
(Verdin et al., 1993). These PCR products were used to generate
labeled probe using [α-32P] CTP and the Rediprime II DNA labeling
system, then puriﬁed using Illustra ProbeQuant G-50 micro col-
umns according to manufacturer's instructions (GE Healthcare).
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as described elsewhere (Barish
et al., 2010). J-Lat cells were cross-linked after drug treatments. To
detect chromosomal ﬂanking regions, pellets were sonicated
(Bioruptor sonicator) to obtain DNA fragments of 100–400 nt.
Chromatin immunoprecipitations were performed with an anti-
body directed against RNA pol II (catalog no. sc-899, Santa Cruz
Biotechnology). Quantitative real-time PCR reactions were per-
formed as described above using 200 nM each primer speciﬁc for
the HIV LTR U3, 50- GACTGCTGACATCGAGCTTTCTACAAG-30 and
50- AAGCAGCTGCTTATATGTAGCATCTGAG-30, the GAPDH promoter
region, 50-TACTAGCGGTTTTACGGGCG-30 and 50-TCGAACAGGAG-
GAGCAGAGAGCGA-30, or a portion of chromosome 12 that is not
near identiﬁed open reading frames, 50-GGCGACTTGACTTCAGA-
GACAATG-30 and 50-GGAAAGAGGATGAGAAAGGCAGG-30.
Resting T cell model of HIV latency
Primary CD4þ T cells were isolated by negative selection
(RosetteSep, Stem Cell Technologies) from peripheral blood of
healthy volunteer donors. A portion of the cells was maintained
in culture (RPMI medium with 5% human AB serum) without
stimulation, for 5 days. Another cell aliquot was stained with
carboxyﬂuorescein diacetate, succinimidyl ester (CFSE, 10 mM,
Molecular Probes) and held overnight. These stained cells were
then infected with replication-competent NL4-3 and cultured in
microplates with immobilized α-CD3 and α-CD28 antibodies to
induce cell proliferation and productive HIV replication (Spina
et al., 1997). After 4 days with stimulus, the CFSE-stained, infected
and proliferating cells were collected and mixed with the unsti-
mulated, unstained, and uninfected autologous CD4þ cells. The
mixed co-culture was maintained for 3 days, with initial addition
of exogenous rIL-2 (5 U/ml, NIH AIDS Research & Reference
Reagent Program) and IL-15 (10 ng/ml, R&D Systems). On day 7,
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the non-dividing CFSE-negative subpopulation (“bystander cells”)
was isolated by ﬂow cytometry cell sorting using a MoFlo XDP
instrument (Beckman-Coulter). The recovered resting cells, carry-
ing non-productive latent HIV infection, were cultured in fresh
medium for 2 additional days before being used in subsequent
experiments (Spina et al., 2013). Maximal HIV reactivation
was induced using immobilized α-CD3/α-CD28 in the presence
of the integrase inhibitor raltegravir (0.1 mM). The level of virus
reactivation was measured by qRT-PCR quantiﬁcation of cell-
associated tat RNA, normalized per 108 copies cellular 18S RNA,
as described above.
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